Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis

NCT02244606 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

27

Enrollment

INDUSTRY

Sponsor class

Conditions

Mycoses
Candidiasis, Invasive
Candidemia

Interventions

DRUG: SCY-078
DRUG: Fluconazole
DRUG: Micafungin

Sponsor

Scynexis, Inc.